(Q24295214)

16

0 references

Gyun Min Lee

12

object named as

Gyun Min Lee

0 references

author name string

Young Jun Koh

1

0 references

Hak-Zoo Kim

2

0 references

Seong-Ik Hwang

3

0 references

Jeung Eun Lee

4

0 references

Nuri Oh

5

0 references

Keehoon Jung

6

0 references

Minah Kim

7

0 references

Kyung Eun Kim

8

0 references

Homin Kim

9

0 references

Nam-Kyu Lim

10

0 references

Choon-Ju Jeon

11

0 references

Do-Hyun Nam

14

0 references

Hoon Ki Sung

15

0 references

Ook Joon Yoo

17

0 references

Gou Young Koh

VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier

18

0 references

language of work or name

English

0 references

publication date

9 August 2010

0 references

published in

Cancer Cell

0 references

volume

18

0 references

issue

2

0 references

page(s)

171-84

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

1 reference

7 January 2021

Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

Angiogenesis as a therapeutic target

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

Molecular regulation of vessel maturation

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

Modes of resistance to anti-angiogenic therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

Angiogenesis: an organizing principle for drug discovery?

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

VEGF-Trap: a VEGF blocker with potent antitumor effects

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

Structure of the Extracellular Domain of Tie Receptor Tyrosine Kinases and Localization of the Angiopoietin-binding Epitope

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

Profound but Dysfunctional Lymphangiogenesis via Vascular Endothelial Growth Factor Ligands from CD11b+ Macrophages in Advanced Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

Angiopoietin: a TIE(d) balance in tumor angiogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.07.001

7 January 2021

10.1016/J.CCR.2010.07.001

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

405863

405863

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference